Can interruption/withdrawl of anti-retroviral therapy provide personalized immunotherapy against HIV-1?

被引:6
|
作者
Bretscher, Peter A. [1 ]
Al-Yassin, Ghassan [1 ]
机构
[1] Univ Saskatchewan, Coll Med, Dept Biochem Microbiol & Immunol, Hlth Sci Bldg,107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada
关键词
anti-retroviral therapy; biomarker for cessation of ART; immunotherapy of HIV-1; LEISHMANIA-MAJOR; SUSCEPTIBLE MICE; IMMUNE-RESPONSE; IGG2; ANTIBODIES; TH1/TH2; NATURE; INFECTION; CELLS; HYPERSENSITIVITY; NONPROGRESSORS; IMMUNIZATION;
D O I
10.1111/sji.12934
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We propose a treatment of HIV-1(+)individuals designed to harness protective immunity, lead to viral containment, and so render the individual minimally infectious. A few HIV-infected individuals, 'elite controllers', generate a stable Th1, cytotoxic T lymphocyte response that contains the virus. Most infected individuals, in the absence of therapy, first generate a similarly protective response that evolves with time a Th2 component, associated with antibody production and loss of viral control. Cessation of anti-retroviral treatment after three years results in viral rebound in most, but about one in seven individuals contains the virus, so-called post-treatment controllers. We suggest an understanding, of how the Th1/Th2 phenotype of immune responses is controlled, can explain these different outcomes and leads us to propose a non-invasive, personalized strategy of immunotherapy. We propose that monitoring the relative prevalence of HIV-1 specific IgG(1)and IgG(2)antibodies can provide a biomarker for deciding when to interrupt/withdraw anti-retroviral therapy to optimally harness protective immunity.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] HIV-1 rebound after anti-retroviral therapy
    Ho, DD
    Zhang, LQ
    [J]. NATURE MEDICINE, 2000, 6 (07) : 736 - 737
  • [2] HIV-1 rebound after anti-retroviral therapy
    David D. Ho
    Linqi Zhang
    [J]. Nature Medicine, 2000, 6 : 736 - 737
  • [3] Numerical modelling of the perturbation of HIV-1 during combination anti-retroviral therapy
    Gumel, AB
    Loewen, TD
    Shivakumar, PN
    Sahai, BM
    Yu, P
    Garba, ML
    [J]. COMPUTERS IN BIOLOGY AND MEDICINE, 2001, 31 (05) : 287 - 301
  • [4] A possible origin of emerged HIV-1 after interrupting anti-retroviral therapy
    Matsumura, Jiro
    Shimizu, Masumi
    Omi, Kyoko
    Nagata, Naoyoshi
    Shinya, Eiji
    Oka, Shinichi
    Takahashi, Hidemi
    [J]. BIOMEDICAL RESEARCH-TOKYO, 2014, 35 (01): : 1 - 8
  • [5] Development of anti-retroviral resistance of HIV-1 infected individuals on therapy: Is it inevitable?
    Kolber, MA
    Campo, RE
    Dickinson, GM
    [J]. IUBMB LIFE, 2004, 56 (06) : 301 - 307
  • [6] HIV-1 group O sensitivity to anti-retroviral drugs
    Descamps, D
    Collin, G
    LoussertAjaka, I
    Bouchaud, O
    Simon, F
    Sarragosti, S
    BrunVezinet, F
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1995, 10 : 18 - 18
  • [7] Resistance to anti-retroviral therapy in Chilean patients with HIV-1 from 2002 to 2005
    Afani, Alejandro S.
    Orellana, Laura R.
    Duarte, Paula J.
    Acevedo, Wiliam M.
    Morales, Omar B.
    Wolff, Marcelo R.
    Vasquez, Patricia
    Beltran, Carlos
    [J]. REVISTA MEDICA DE CHILE, 2007, 135 (10) : 1237 - 1244
  • [8] Autoantibodies Among HIV-1 Infected Individuals and the Effect of Anti-Retroviral Therapy (ART) on It
    Steve, Runal John
    Alex, Diviya
    Yesudhason, Binesh Lal
    Prakash, John Antony Jude
    Mathews, Nitty Skari-ah
    Daniel, Dolly
    Ramalingam, Veena Vadhini
    Demosthenes, John Paul
    Ghale, Ben Chirag
    Anantharam, Raghavendran
    Rebekah, Grace
    Rupali, Priscilla
    Varghese, George Mannil
    Kannangai, Rajesh
    [J]. CURRENT HIV RESEARCH, 2021, 19 (03) : 277 - 285
  • [9] The effectiveness of anti-retroviral drug therapy for HIV-1 is associated with HIV-1 proviral DNA levels and viral selection
    Ariyama, I
    Chong, Y
    Murata, M
    Nabeshima, S
    Ikematsu, H
    Kashiwagi, S
    Hayashi, J
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2002, 30 (03) : 289 - 300
  • [10] Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy
    Mark E. Sharkey
    Ian Teo
    Thomas Greenough
    Natalia Sharova
    Katherine Luzuriaga
    John L. Sullivan
    R. Pat Bucy
    Leondios G. Kostrikis
    Ashley Haase
    Claire Veryard
    Raul E. Davaro
    Sarah H. Cheeseman
    Jennifer S. Daly
    Carol Bova
    Richard T. Ellison
    Brian Mady
    Kwan Kew Lai
    Graeme Moyle
    Mark Nelson
    Brian Gazzard
    Sunil Shaunak
    Mario Stevenson
    [J]. Nature Medicine, 2000, 6 : 76 - 81